Characterization of Two New Monoclonal Antibodies Against Human Papillomavirus Type 16 L1 Protein

Overview

Journal Diagn Pathol

Publisher Biomed Central

Specialty Pathology

Date 2014 Jun 3

PMID 24884993

Citations 4

Authors

Yan Wang

Qinglong Shang

Weizhen Xu

Di Li

Hongxi Gu

Lanlan Wei

Affiliations

Soon will be listed here.

Abstract

Background: Human papillomavirus type 16 (HPV16) infection is implicated in cervical carcinogenesis. This study aimed to characterize two new monoclonal antibodies (mAbs) against HPV L1 protein.

Methods: The immunocompetence of AE3 and AG7 mAbs for HPV L1 protein was evaluated by Western blot analysis, immunostaining, hemagglutination inhibition assay, and ELISA. The heavy chain variable region (VH) and light chain variable region (VL) of AE3 and AG7 mAbs were sequenced and analyzed.

Results: Both mAbs specifically recognized HPV16 L1 and virus-like particles (VLPs). Both the affinity and the titer of AE3 mAb were higher than that of AG7. There were differences in sequences in the complementary determining regions (CDR) 2 and 3 of VL, as well as in the CDR1 and CDR3 of VH. The two mAbs have distinct predicted three-dimensional structures.

Conclusions: We characterized two mAbs neutralizing antibodies for HPV L1 protein, which would help develop genetic-engineered neutralizing antibodies against HPV16 for diagnostic and therapeutic purposes.

Citing Articles

Cross-neutralizing antibody titres against non-vaccine types induced by a recombinant trivalent HPV vaccine (16/18/58) in rhesus macaques.

Wang Y, Liu Y, Liang S, Yin F, Zhang H, Liu Y Papillomavirus Res. 2020; 10:100209.

PMID: 33197649 PMC: 7704424. DOI: 10.1016/j.pvr.2020.100209.

Advances in Designing and Developing Vaccines, Drugs and Therapeutic Approaches to Counter Human Papilloma Virus.

Dadar M, Chakraborty S, Dhama K, Prasad M, Khandia R, Hassan S Front Immunol. 2018; 9:2478.

PMID: 30483247 PMC: 6240620. DOI: 10.3389/fimmu.2018.02478.

Development and characterization of an HPV18 detection kit using two novel HPV18 type-specific monoclonal antibodies.

Zhang Y, He Y, Li L, Liang S, Yan M, Ren D Diagn Pathol. 2018; 13(1):55.

PMID: 30115088 PMC: 6097307. DOI: 10.1186/s13000-018-0727-7.

Immunotherapeutic strategies for sexually transmitted viral infections: HIV, HSV and HPV.

Wahid B, Ali A, Idrees M, Rafique S Cell Immunol. 2016; 310:1-13.

PMID: 27514252 PMC: 7124316. DOI: 10.1016/j.cellimm.2016.08.001.

References

Kreimer A, Clifford G, Boyle P, Franceschi S . Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review. Cancer Epidemiol Biomarkers Prev. 2005; 14(2):467-75. DOI: 10.1158/1055-9965.EPI-04-0551. View

Ohlschlager P, Osen W, Dell K, Faath S, Garcea R, Jochmus I . Human papillomavirus type 16 L1 capsomeres induce L1-specific cytotoxic T lymphocytes and tumor regression in C57BL/6 mice. J Virol. 2003; 77(8):4635-45. PMC: 152157. DOI: 10.1128/jvi.77.8.4635-4645.2003. View

Matsukura T, Sugase M . Pitfalls in the epidemiologic classification of human papillomavirus types associated with cervical cancer using polymerase chain reaction: driver and passenger. Int J Gynecol Cancer. 2008; 18(5):1042-50. DOI: 10.1111/j.1525-1438.2007.01157.x. View

Luciani S, Jauregui B, Kieny C, Andrus J . Human papillomavirus vaccines: new tools for accelerating cervical cancer prevention in developing countries. Immunotherapy. 2010; 1(5):795-807. DOI: 10.2217/imt.09.48. View

Schiller J, Lowy D . Papillomavirus-like particle based vaccines: cervical cancer and beyond. Expert Opin Biol Ther. 2001; 1(4):571-81. DOI: 10.1517/14712598.1.4.571. View

De Vuyst H, Clifford G, Li N, Franceschi S . HPV infection in Europe. Eur J Cancer. 2009; 45(15):2632-9. DOI: 10.1016/j.ejca.2009.07.019. View

Fraser C, Tomassini J, Xi L, Golm G, Watson M, Giuliano A . Modeling the long-term antibody response of a human papillomavirus (HPV) virus-like particle (VLP) type 16 prophylactic vaccine. Vaccine. 2007; 25(21):4324-33. DOI: 10.1016/j.vaccine.2007.02.069. View

Wilson N, Simpson R, Cooper-Liddell C . Introductory glycosylation analysis using SDS-PAGE and peptide mass fingerprinting. Methods Mol Biol. 2009; 534:205-12. DOI: 10.1007/978-1-59745-022-5_15. View

Frazer I . Cervical cancer vaccine development. Sex Health. 2010; 7(3):230-4. DOI: 10.1071/SH09132. View

10.

Carestiato F, da Silva K, Balthazar D, Silva L, Marinho M, Oliveira L . Analysis of molecular biology techniques for the diagnosis of human papillomavirus infection and cervical cancer prevention. Rev Soc Bras Med Trop. 2006; 39(5):428-32. DOI: 10.1590/s0037-86822006000500002. View

11.

Franceschi S . The IARC commitment to cancer prevention: the example of papillomavirus and cervical cancer. Recent Results Cancer Res. 2005; 166:277-97. DOI: 10.1007/3-540-26980-0_18. View

12.

Garcia-Espinosa B, Moro-Rodriguez E, Alvarez-Fernandez E . Human papillomavirus genotypes in human immunodeficiency virus-positive patients with anal pathology in Madrid, Spain. Diagn Pathol. 2013; 8:204. PMC: 3937168. DOI: 10.1186/1746-1596-8-204. View

13.

Mageed R, Harmer I, Wynn S, Moyes S, Maziak B, Bruggemann M . Rearrangement of the human heavy chain variable region gene V3-23 in transgenic mice generates antibodies reactive with a range of antigens on the basis of VHCDR3 and residues intrinsic to the heavy chain variable region. Clin Exp Immunol. 2001; 123(1):1-8. PMC: 1905971. DOI: 10.1046/j.1365-2249.2001.01380.x. View

14.

Matoba N, Kajiura H, Cherni I, Doran J, Bomsel M, Fujiyama K . Biochemical and immunological characterization of the plant-derived candidate human immunodeficiency virus type 1 mucosal vaccine CTB-MPR. Plant Biotechnol J. 2008; 7(2):129-45. DOI: 10.1111/j.1467-7652.2008.00381.x. View

15.

Chen P . Structural analyses of human developmentally regulated Vh3 genes. Scand J Immunol. 1990; 31(3):257-67. DOI: 10.1111/j.1365-3083.1990.tb02767.x. View